GeoVax Labs, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 4.04 million compared to USD 2.43 million a year ago. Basic loss per share from continuing operations was USD 2.25 compared to USD 5.1 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.76 USD | +7.98% | +9.32% | -67.50% |
05-14 | Transcript : GeoVax Labs, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
03-28 | GeoVax Labs, Inc. to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-67.50% | 4.12M | |
+48.67% | 58.71B | |
-2.76% | 41.31B | |
+36.42% | 39.2B | |
-11.22% | 27.4B | |
+9.25% | 26.55B | |
-23.10% | 18.98B | |
+1.88% | 12.51B | |
+26.43% | 12.08B | |
+21.74% | 11.94B |
- Stock Market
- Equities
- GOVX Stock
- News GeoVax Labs, Inc.
- GeoVax Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023